Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
for
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation,
Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy
for
Prostate Cancer
Location: New York NY
Sponsor: NYU Langone Health
Sex: Male
Age: 18+
Code: NCT06542757
Recruiting
Jump: MR Simulation For Radiation Therapy Master Protocol